TheraRadar
Clinical-Stage Companies / Basilea Pharmaceutica

Basilea Pharmaceutica

Pre-Approval PRO BETA
40
Total Trials
6
Phase 3
10
Phase 2
4
Recruiting
270
Score

Pipeline by Phase

Phase 3
6
Phase 2
10
Phase 1
30

Therapeutic Focus

Pharmacokinetics Fungal Infection Candidemia Healthy Volunteers Healthy

Clinical Trials (40)

NCT06925321 Phase 3 RECRUITING

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Started: 8/26/2025

NCT05421858 Phase 3 RECRUITING

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

Started: 12/11/2024

NCT05856227 Phase 3 COMPLETED

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

Started: 8/6/2023

NCT03138733 Phase 3 COMPLETED

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

Started: 8/26/2018

NCT03439124 Phase 3 COMPLETED

Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia

Started: 11/27/2017

NCT03137173 Phase 3 COMPLETED

Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections

Started: 2/19/2018

NCT04240886 Phase 2 TERMINATED

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

Started: 1/4/2020

NCT04148287 Phase 2 COMPLETED

An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris

Started: 12/13/2019

NCT03604705 Phase 2 COMPLETED

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

Started: 10/3/2018

NCT03230318 Phase 2 COMPLETED

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Started: 9/28/2017

NCT07500181 Phase 1 RECRUITING

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

Started: 3/4/2026

NCT06733675 Phase 1 RECRUITING

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

Started: 1/7/2025

NCT06961708 Phase 1 COMPLETED

A Study of Fosmanogepix in Healthy Adult Chinese Subjects

Started: 4/14/2025

NCT06665555 Phase 1 COMPLETED

Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age

Started: 11/4/2024

NCT05582187 Phase 1 COMPLETED

A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.

Started: 10/31/2022

NCT05488678 Phase 1 COMPLETED

Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function

Started: 10/12/2022

NCT05527834 Phase 1 COMPLETED

Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants

Started: 9/13/2022

NCT04877379 Phase 1 COMPLETED

VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers

Started: 6/8/2021

NCT04243863 Phase 1 COMPLETED

VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers

Started: 1/20/2020

NCT04314206 Phase 1 COMPLETED

VNRX-5024 Safety and PK in Healthy Adult Volunteers

Started: 7/27/2020

NCT02956499 Phase 1 COMPLETED

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

Started: 5/24/2016

NCT02957929 Phase 1 COMPLETED

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Started: 10/31/2016

NCT06808646 Phase 1 COMPLETED

A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin

Started: 1/17/2025

NCT05491733 Phase 1 COMPLETED

A Bioequivalence Study of APX001 High-load and Low-load Tablets

Started: 3/2/2021

NCT02490800 Phase 1 COMPLETED

Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma

Started: 5/20/2015

NCT03250299 Phase 1 TERMINATED

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Started: 12/15/2017

NCT04804059 Phase 1 COMPLETED

A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy Males

Started: 8/17/2018

NCT03333005 Phase 1 COMPLETED

Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia

Started: 11/27/2017

NCT04166669 Phase 1 COMPLETED

A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001

Started: 11/12/2019

NCT04604132 Phase 1 TERMINATED

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

Started: 10/6/2020

NCT04045613 Phase 1 COMPLETED

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

Started: 8/2/2019

NCT01752920 Phase 1 COMPLETED

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Started: 12/10/2012

NCT02527681 Phase 1 TERMINATED

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

Started: 11/22/2016

NCT01397929 Phase 1 COMPLETED

An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid Tumors

Started: 6/1/2011

NCT02895360 Phase 1 COMPLETED

Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent Glioblastoma

Started: 8/24/2016

NCT04098692 Phase 1 COMPLETED

Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male Subjects

Started: 8/8/2019

NCT00771524 Phase 1 COMPLETED

Pharmacokinetic Study of the Penetration of Ceftobiprole in the Bone

Started: 4/1/2009

NCT00770978 Phase 1 COMPLETED

Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU

Started: 11/1/2008

NCT00771719 Phase 1 TERMINATED

Open Label Pharmacokinetic in Adult Patients With Ventilator-Associated Pneumonia

Started: 10/1/2008

NCT00965042 Phase 1 COMPLETED

Effect of Ceftobiprole on Human Intestinal Microflora

Started: 4/1/2009

Drug Candidates

Fosmanogepix IV infusion Standard of care antifungal therapy Fosmanogepix oral tablet Oral Fosmanogepix IV Fosmanogepix IV placebo oral placebo BAL2420 or placebo Fosmanogepix Caspofungin
Activity Status: Active
Last Trial Started: 3/4/2026
Last Trial Ended: 10/16/2025
Trials (12 months): 2
Completed Trials: 31
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.